Cyted Health Inc
Developer and operator of a non-endoscopic diagnostic platform for esophageal disease. Offers a minimally invasive capsule-sponge cell collection procedure combined with molecular methylation-based biomarker testing, machine-learning analytics, accredited laboratory reporting and clinical services. Activities include clinical validation studies and large population screening programs, nurse-led community deployment, regulatory clearances, and commercial scale-up in the UK with ongoing expansion into the US.
Industries
N/A
Nr. of Employees
small (1-50)
Cyted Health Inc
149 Cherry Hinton Road, Cambridge, CB1 7BX, United Kingdom
Products
Minimally invasive capsule-sponge cell collection device
A swallowable capsule and expandable sponge system designed to sample cells across the esophagus for diagnostic molecular analysis without endoscopy or sedation.
Molecular diagnostic assays for esophageal conditions
Laboratory molecular assays and biomarker panels run on collected esophageal cells to detect markers of Barrett's esophagus, esophageal adenocarcinoma and inflammatory conditions, with methylation-based readouts.
Minimally invasive capsule-sponge cell collection device
A swallowable capsule and expandable sponge system designed to sample cells across the esophagus for diagnostic molecular analysis without endoscopy or sedation.
Molecular diagnostic assays for esophageal conditions
Laboratory molecular assays and biomarker panels run on collected esophageal cells to detect markers of Barrett's esophagus, esophageal adenocarcinoma and inflammatory conditions, with methylation-based readouts.
Services
ISO 15189-compliant laboratory services for processing, analysis and standardized reporting of esophageal capsule-sponge samples, delivered via in-house or partnered accredited laboratories.
Nurse-delivered, minimally invasive esophageal cell collection service for screening and surveillance, designed for use in community clinics, primary care and hospital settings.
Operational and scientific support for screening and validation studies, including large population screening trials and multi-site clinical validation studies across the UK and US.
Biomarker discovery, molecular assay development, methylation analysis, statistical modelling and machine learning support for diagnostic test development and predictive modelling.
Software solutions to support ordering, sample tracking, reporting and integration with customer IT systems to automate workflows and deliver results.
ISO 15189-compliant laboratory services for processing, analysis and standardized reporting of esophageal capsule-sponge samples, delivered via in-house or partnered accredited laboratories.
Nurse-delivered, minimally invasive esophageal cell collection service for screening and surveillance, designed for use in community clinics, primary care and hospital settings.
Operational and scientific support for screening and validation studies, including large population screening trials and multi-site clinical validation studies across the UK and US.
Biomarker discovery, molecular assay development, methylation analysis, statistical modelling and machine learning support for diagnostic test development and predictive modelling.
Software solutions to support ordering, sample tracking, reporting and integration with customer IT systems to automate workflows and deliver results.
Expertise Areas
- Minimally invasive diagnostic sampling for the esophagus
- Molecular biomarker discovery and assay validation (methylation-based)
- Machine learning and statistical modelling for diagnostics
- Clinical trial management and large-scale population screening
Key Technologies
- Minimally invasive capsule-sponge cell sampling
- Methylation-based molecular assays
- Molecular diagnostic panels for cell-based samples
- Image-based deep learning
News & Updates
First close of $44 million Series B financing to accelerate US expansion and product portfolio growth.
Regulatory clearance (FDA 510(k)) for the minimally invasive capsule-sponge sampling device in the United States.
Awarded Best Medical Technology at the Prix Galien Awards.
Awarded Best Provider of Diagnostic Services in partnership with NHS Scotland.
Launch of a large population screening trial for Barrett’s esophagus using capsule-sponge testing (BEST4) with planned broad patient invitations.
Enrollment of first patients in the DETECT-ME multi-site US clinical validation study evaluating molecular assays using capsule-sponge collected esophageal cells.
First close of $44 million Series B financing to accelerate US expansion and product portfolio growth.
Regulatory clearance (FDA 510(k)) for the minimally invasive capsule-sponge sampling device in the United States.
Awarded Best Medical Technology at the Prix Galien Awards.
Awarded Best Provider of Diagnostic Services in partnership with NHS Scotland.
Launch of a large population screening trial for Barrett’s esophagus using capsule-sponge testing (BEST4) with planned broad patient invitations.
Enrollment of first patients in the DETECT-ME multi-site US clinical validation study evaluating molecular assays using capsule-sponge collected esophageal cells.